BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, April 4, 2026
Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
Neurology/psychiatric RSS Feed RSS

Illustration of man holding magnifying glass to human body model showing muscle anatomy
Neurology/psychiatric

SPAST-AAV9 gene therapy prevents hereditary spastic paraplegia symptoms

Dec. 31, 2025
No Comments
In a recent publication in Molecular Therapy, researchers from Drexel University College of Medicine and UMass Chan Medical School presented a silence-and-replace gene therapy strategy aiming to address both the gain-of-toxicity and loss-of-function components of the disease hereditary spastic paraplegia (HSP).
Read More
Illustration of human brain and dna
Neurology/psychiatric

Gene therapy restores SynGAP1 function, rescues epilepsy and behaviors

Dec. 31, 2025
No Comments
SYNGAP1-related disorders (SRDs) are rare neurodevelopmental conditions characterized by a wide range of symptoms, including intellectual disability, epilepsy, motor deficits and increased risk-taking behavior.
Read More
Icons representing scientific research
The year in review

Science in 2025: the best of the rest

Dec. 31, 2025
By Mar de Miguel and Anette Breindl
No Comments
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Read More
Children’s Hospital of Philadelphia
The year in review

2025 marks a breakthrough year for in vivo gene therapies

Dec. 30, 2025
By Mar de Miguel
No Comments
Gene editing technologies are moving forward in preclinical development with innovative strategies designed to treat diseases at their root and even reverse them.
Read More
Children’s Hospital of Philadelphia
The year in review

2025 marks a breakthrough year for in vivo gene therapies

Dec. 30, 2025
By Mar de Miguel
No Comments
Gene editing technologies are moving forward in preclinical development with innovative strategies designed to treat diseases at their root and even reverse them. However, many approaches still struggle to reach target cells or tissues – either they fail to arrive, or their efficacy is low. In vivo therapies face numerous challenges, but despite these hurdles, 2025 has marked a year of remarkable progress.
Read More
Neurology/psychiatric

New Nav1.8 blockers disclosed in Chengdu Easton Biopharmaceuticals patent

Dec. 30, 2025
Chengdu Easton Biopharmaceuticals Co. Ltd. has divulged sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia, cough, urinary incontinence and multiple sclerosis.
Read More
Neurology/psychiatric

Neurodawn Pharmaceutical divulges new PDE3A inhibitors

Dec. 30, 2025
Neurodawn Pharmaceutical Co. Ltd. has synthesized phosphodiesterase PDE3A inhibitors reported to be useful for the treatment of dementia and cerebrovascular disorders.
Read More
Demyelination of a neuron
Neurology/psychiatric

Apoptotic body-like liposomes restore immune tolerance in MS

Dec. 30, 2025
No Comments
Multiple sclerosis (MS) is a chronic immune-mediated disease characterized by the destruction of myelin sheaths, neuroaxonal damage, glial cell activation and formation of demyelinated plaques in the CNS. Since MS is considered a prototypic antigen-specific autoimmune disease, restoring immune tolerance to self-antigens is being explored as a therapeutic strategy.
Read More
South Korea flag on blurred background
The year in review

Top issues in South Korea’s biotechnology sector in 2025

Dec. 30, 2025
By Marian (YoonJee) Chu
No Comments
U.S. policy, China’s strategic rise, blockbuster deals and AI dominated South Korea’s biotechnology industry this year, with U.S. tariffs and the Biosecure Act’s hitch onto 2026 legislation serving as major topics of speculation.
Read More
South Korea flag on blurred background
The year in review

Top issues in South Korea’s biotechnology sector in 2025

Dec. 29, 2025
By Marian (YoonJee) Chu
No Comments
U.S. policy, China’s strategic rise, blockbuster deals and AI dominated South Korea’s biotechnology industry this year, with U.S. tariffs and the Biosecure Act’s hitch onto 2026 legislation serving as major topics of speculation.
Read More
Previous 1 2 … 23 24 25 26 27 28 29 30 31 … 3016 3017 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 2, 2026.
  • Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

    Small-molecule TREM2 agonist advances to treat Alzheimer’s

    BioWorld Science
    Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
  • Amyloid beta peptides on neurons

    Amlogenyx’s AM-805 reduces amyloid plaques in AD

    BioWorld Science
    The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 31, 2026
  • Atai Therapeutics patents new 5-HT2 receptor agonists

    BioWorld Science
    Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing